Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

Novo Nordisk is working on a new obesity drug that could help patients ... The team has an Overweight rating on Novo stock ...

Germany-based Evotec SE (NASDAQ:EVO) is trading on Monday after a report that suggests the company is a takeover target. The ...

The stock is now heading for an eye-popping annual gain of over ... Learn more here. Market leaders Novo Nordisk and Eli ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...

ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak sales of around $400 million in anaphylaxis treatment.

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Investing.com -- Novo Nordisk (CSE: NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches a pivotal moment in its development pipeline.

(Reuters) - U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk (NYSE: NVO )'s highly in-demand drugs for diabetes and weight loss, according to a review of patient data ...